MEDINCELL S.A. EO-,01

Medincell will propose the election of Dr. Elisabeth Svanberg as an independent member of the board of directors at the general meeting on 30 September 2026 and plans to appoint her chair of the remuneration and nomination committee. Her appointment would form part of an ongoing board renewal since 2025 and is intended to strengthen international expertise for the company’s next development phase. Shareholders will also vote on a procedure for the future appointment of an employee representative; two existing members are stepping down. » Mere på de.investing.com

Medincell has secured €48 million from institutional investors in a private placement through the issuance of 2,370,000 new shares at €20.35 each (a 10% discount to the closing price on 5 March 2026). The new shares represent 7.1% of the share capital before the placement (6.6% afterwards); participating investors include Perceptive Advisors, Kurma Growth Opportunities Fund, Affinity Asset Advisors and Polar Capital. The company plans to use the proceeds to expand partnership programs, optimize future licensing structures and strengthen its BEPO technology for long-acting injectables; the capital increase improves the balance sheet (current ratio 2.88). Settlement and admission to trading on Euronext Paris are expected on 10 March 2026; Medincell remains unprofitable but recently reported revenue of $38 million (+146% YoY). » Mere på de.investing.com

Medincell has initiated an accelerated bookbuilding for a private placement of around 6% of its share capital and may issue up to 5,749,064 new shares. Net proceeds are intended to expand partnerships, strengthen future collaborations and advance the BEPO technology platform for long-acting injectables; funds may also be used for general corporate purposes. The placement is being carried out with subscription rights excluded, settlement is planned for 10 March 2026, and board members signed 90-day lock-ups; analysts mostly maintain buy recommendations. » Mere på de.investing.com

Medincell increased revenue in the first half of 2025 by 50% to €14m, mainly driven by license income and R&D partnerships. Operating expenses rose 22%, resulting in an operating loss of €6.6m and causing the stock to drop 6.63% after the results. Cash reserves of €53m are expected to last about two years; approvals for UZEDY and olanzapine LAI and the partnership with AbbVie should support future growth. Management aims to return to profitability in 2026–2027, but risks remain from rising costs, competition and dependence on approvals. » Mere på de.investing.com